Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 138, Issue 4, Pages e2 (April 2010)

Similar presentations


Presentation on theme: "Volume 138, Issue 4, Pages e2 (April 2010)"— Presentation transcript:

1 Volume 138, Issue 4, Pages 1365-1373.e2 (April 2010)
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection  John McHutchison, Zachary Goodman, Keyur Patel, Hala Makhlouf, Maribel Rodriguez–Torres, Mitchell Shiffman, Don Rockey, Petr Husa, Wan–Long Chuang, Robert Levine, Mark Jonas, Dickens Theodore, Richard Brigandi, Alison Webster, Margaret Schultz, Helen Watson, Britt Stancil, Stephen Gardner  Gastroenterology  Volume 138, Issue 4, Pages e2 (April 2010) DOI: /j.gastro Copyright © 2010 AGA Institute Terms and Conditions

2 Figure 1 Paired liver biopsy specimens from a single patient stained with picrosirius red for collagen. Baseline biopsy specimen (left) has fraction of pixels positive for collagen of Week 52 biopsy specimen (right) clearly has more red staining and by morphometry has of the total pixels positive for collagen. Gastroenterology  , e2DOI: ( /j.gastro ) Copyright © 2010 AGA Institute Terms and Conditions

3 Figure 2 High magnification of liver biopsy specimens from same patient in Figure 1, stained for SMA to demonstrate activated stellate cells. In baseline biopsy specimen (left), the fraction of darkly stained pixels is of total pixels. In the week 52 biopsy specimen (right), of the total pixels are positive for SMA. Gastroenterology  , e2DOI: ( /j.gastro ) Copyright © 2010 AGA Institute Terms and Conditions

4 Figure 3 Change from baseline in steatosis grade at week 52. There was no significant change at week 52 in overall steatosis grades between the groups, although there is a trend towards improvement in the proportion of patients with grade 2 (6%–33%) or 3 (34%–66%) steatosis in the farglitizar 1-mg cohort. Gastroenterology  , e2DOI: ( /j.gastro ) Copyright © 2010 AGA Institute Terms and Conditions

5 Supplementary Figure 1 Of 585 CHC patients with screening biopsy, 265 were randomized to receive placebo (n = 88), Farglitizar 0.5 mg (n = 89) or 1.0 mg (n = 88). Most patients were able to complete study assessments, with reasons for discontinuation as shown. Gastroenterology  , e2DOI: ( /j.gastro ) Copyright © 2010 AGA Institute Terms and Conditions


Download ppt "Volume 138, Issue 4, Pages e2 (April 2010)"

Similar presentations


Ads by Google